{"data":{"id":"us-ne/neb.-rev.-stat.-71-9602","jurisdiction":"us-ne","citation":"Neb. Rev. Stat. § 71-9602","heading":"Neb. Rev. Stat. § 71-9602","body":"For purposes of the Investigational Drug Use Act:\n\n(1) Advanced illness means any progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of federally approved and available treatments, and that, without life-sustaining procedures, would likely result in death within six months;\n\n(2) Eligible patient means a person who meets the requirements of section 71-9603 ;\n\n(3) Health care provider has the same meaning as in section 71-7907 ;\n\n(4) Investigational drug, biological product, or device means any drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration;\n\n(5) Physician means any person who is licensed to practice medicine and surgery pursuant to the Medicine and Surgery Practice Act; and\n\n(6) Written, informed consent means a writing which conforms to section 71-9604 .","path":["NE Code","Chapter 71"],"source_url":"https://nebraskalegislature.gov/laws/statutes.php?statute=71-9602","current_through":"2026-08-14","vintage":"open-us-law v2026.08, retrieved 2026-09-14","retrieved_at":"2026-09-14T18:32:21Z","sha256":"9445d824b125596a7a2a3a20ffc403e23f6eceb659f32d63bf69d769785f88c5","source_id":"us-ne","stale":false,"prev":"us-ne/neb.-rev.-stat.-71-9601","next":"us-ne/neb.-rev.-stat.-71-9603"},"notice":"GroundRules: Original legal text. Not legal advice."}